Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17416403 | METHOD OF TREATING CANCER USING A HISTONE ACETYLTRANSERACE ACTIVATOR WITH IFN¿ AND AN IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | The Regents of the University of California |
| 18429887 | Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18019467 | TREATMENT OF CLL | Final Rejection | NOVARTIS AG |
| 18019469 | TREATMENT OF B CELL MALIGNANCIES | Final Rejection | NOVARTIS AG |
| 17921793 | PHARMACEUTICAL FORMULATION | Non-Final OA | AMGEN INC. |
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18010105 | CXCL9 AND VARIANTS THEREOF FOR IMMUNOTHERAPY OF CANCER DISEASES | Final Rejection | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 18177374 | BINDING MOLECULES AGAINST FRa | Non-Final OA | AstraZeneca AB |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | Non-Final OA | Shionogi & Co., Ltd. |
| 18666545 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | Non-Final OA | Bayer Aktiengesellschaft |
| 18003118 | SULFATED PEPTIDES FOR CHEMOKINE RECEPTOR ANTIBODY GENERATION | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18508346 | BINDING MOLECULES FOR THE TREATMENT OF CANCER | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17414970 | BIFUNCTIONAL ANTI-PD-1/IL-7 MOLECULE | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18731402 | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | Non-Final OA | ST PHI THERAPEUTICS CO., LTD. |
| 18043602 | Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer | Non-Final OA | MSD International GmbH |
| 18638420 | ANTI-BCMA ANTIBODIES AND TREATMENT METHODS | Final Rejection | SUTRO BIOPHARMA, INC. |
| 17999469 | HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIB | Non-Final OA | Zymeworks BC Inc. |
| 17280550 | METHODS AND PHARMACEUTICAL COMPOSITION COMPRISING TAFA4 FOR REDUCING SKIN INFLAMMATION | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) |
| 17972867 | MONOCLONAL ANTIBODIES AGAINST C-MET | Non-Final OA | Genmab A/S |
| 18251294 | FULLY HUMAN ANTIBODY TARGETING CD5, AND FULLY HUMAN CHIMERIC ANTIGEN RECEPTOR (CAR) AND APPLICATION THEREOF | Non-Final OA | Nanjing IASO Biotechnology Co., Ltd. |
| 18140892 | CRTAM ANTIBODIES AND METHODS OF TREATING CANCER | Final Rejection | Oxford BioTherapeutics Ltd |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | Non-Final OA | Keros Therapeutics, Inc. |
| 18246939 | ANTI-CLAUDIN18.2 AND CD3 BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. |
| 18010944 | ANTI-CLAUDIN18.2 ANTIBODY AND USE THEREOF | Non-Final OA | FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. |
| 18013504 | ANTI-GITR MONOCLONAL ANTIBODY AND MEDICAL USE THEREOF | Non-Final OA | INNOLAKE BIOPHARMA (HANGZHOU) CO., LTD. |
| 18000064 | ANTI-CD73 ANTIBODY AND USE THEREOF | Non-Final OA | BRIGHTPATH BIOTHERAPEUTICS CO., LTD. |
| 17928136 | ANTIBODIES SPECIFICALLY RECOGNIZING NERVE GROWTH FACTOR AND USES THEREOF | Non-Final OA | STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. |
| 17924540 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Final Rejection | Adagene AG |
| 17789350 | ANTI-OX40 ANTIBODY AND USE THEREOF | Non-Final OA | HIFIBIO INC. |
| 17788926 | ANTIBODIES BINDING BCMA AND USES THEREOF | Final Rejection | Biosion Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy